login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
CITIUS PHARMACEUTICALS INC (CTXR) Stock News
USA
- NASDAQ:CTXR -
US17322U3068
-
Common Stock
1.58
USD
+0.01 (+0.64%)
Last: 10/31/2025, 8:00:01 PM
1.56
USD
-0.02 (-1.27%)
After Hours:
10/31/2025, 8:00:01 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
CTXR Latest News, Press Relases and Analysis
All
Press Releases
11 days ago - By: Chartmill
- Mentions:
GSIT
IBIO
NERV
ADAP
...
These stocks that are showing activity before the opening bell on Tuesday.
11 days ago - By: Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
11 days ago - By: Benzinga
- Mentions:
EXK
SVM
PAAS
PCAR
...
PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
11 days ago - By: Benzinga
- Mentions:
IVA
HBIO
IBIO
NERV
...
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
15 days ago - By: Citius Pharmaceuticals, Inc.
- Mentions:
CTOR
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
16 days ago - By: Citius Oncology, Inc.
- Mentions:
CTOR
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIRâ„¢
2 months ago - By: Citius Oncology, Inc.
- Mentions:
CTOR
Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
2 months ago - By: Citius Oncology, Inc.
- Mentions:
CTOR
Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch
3 months ago - By: The Motley Fool
Citius Posts Wider Loss in Fiscal Q3
3 months ago - By: Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
4 months ago - By: Citius Oncology, Inc.
- Mentions:
CTOR
Citius Oncology Announces Closing of $9.0 Million Public Offering
4 months ago - By: Citius Oncology, Inc.
- Mentions:
CTOR
Citius Oncology Announces Pricing of $9.0 Million Public Offering
4 months ago - By: Citius Oncology, Inc.
- Mentions:
CTOR
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora
4 months ago - By: Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
5 months ago - By: Citius Oncology, Inc.
- Mentions:
CTOR
Citius Oncology Anticipates Commercial Launch of LYMPHIRâ„¢ in 2025
5 months ago - By: Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules
5 months ago - By: Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules
Please enable JavaScript to continue using this application.